Rutherrin looks ready' Theralase has now developed significant expertise and intellectual property of its patented PDCs, in the area of photopharmacology and anti-cancer therapy, with data acquired from preclinical models of human disease. Extensive preclinical research has been conducted with Rutherrin®, a patented formulation of the Company's lead PDC (TLD-1433) combined with transferrin. The Company has demonstrated significant anti-cancer efficacy of Rutherrin®, across numerous preclinical models; including: GlioBlastoma Multiforme ("GBM") and Non-Small Cell Lung Cancer ("NSCLC").'
BTW thanks HempDoc for those treatment/prevention protocols.